LifeSci Capital analyst Sam Slutsky has maintained their neutral stance on IFRX stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Hold rating due to a combination of factors surrounding InflaRx’s current market position and strategic developments in the pharmaceutical industry. The recent licensing deal between Biogen and Vanqua Bio for an oral C5aR1 inhibitor highlights the growing interest in this therapeutic area, which is relevant to InflaRx’s own pipeline. However, there is uncertainty regarding the central nervous system (CNS) penetrance of InflaRx’s INF904, which could impact its competitive edge in the market.
Additionally, the financial metrics of InflaRx, such as its cash burn rate and the years of cash available, suggest a stable but cautious outlook. While the company has more than 1.5 years of cash available, the short interest remains low, indicating limited immediate pressure from investors. These elements collectively contribute to a Hold rating, reflecting a balanced view of potential opportunities and existing uncertainties.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.